Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jiangxi Rimag Group Co., Ltd. Class H ( (HK:2522) ) has provided an update.
Jiangxi Rimag Group Co., Ltd. announced a connected transaction involving a joint and several liability guarantee for a credit facility of up to RMB50 million with XW Bank, in collaboration with Shanghai Ronggongshe. This agreement, which involves Rimag Yuntai and Wuhan Ronggongshe, is subject to specific reporting requirements under the Hong Kong Stock Exchange Listing Rules, reflecting the company’s strategic financial maneuvers to support its subsidiaries and enhance its market positioning in the medical imaging industry.
The most recent analyst rating on (HK:2522) stock is a Sell with a HK$14.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
More about Jiangxi Rimag Group Co., Ltd. Class H
Jiangxi Rimag Group Co., Ltd. is a leading medical group in China, specializing in medical imaging. It operates a medical imaging platform offering diverse imaging services and solutions, including imaging center services, imaging solution services, and Rimag Cloud services.
Average Trading Volume: 10,628,150
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.97B
For an in-depth examination of 2522 stock, go to TipRanks’ Overview page.